ClinVar Miner

Submissions for variant NM_001429.4(EP300):c.4026-9A>G

dbSNP: rs2059153923
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Labcorp Genetics (formerly Invitae), Labcorp RCV002563143 SCV001401014 pathogenic Rubinstein-Taybi syndrome due to EP300 haploinsufficiency 2019-08-06 criteria provided, single submitter clinical testing For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site, but this prediction has not been confirmed by published transcriptional studies. This variant has been observed in individual(s) with clinical features of Rubinstein-Taybi syndrome (PMID: 27648933, Invitae). In at least one individual this variant was found to be de novo. This variant is not present in population databases (ExAC no frequency). This sequence change falls in intron 24 of the EP300 gene. It does not directly change the encoded amino acid sequence of the EP300 protein.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.